Literature DB >> 16882549

Limited P-glycoprotein mediated efflux for anti-epileptic drugs.

Andrew Crowe1, Yee-Khuan Teoh.   

Abstract

A variety of anti-epileptic drugs (AEDs) were tested for their ability to be transported by P-glycoprotein (P-gp) through Caco-2 monolayers using bi-directional (apical (Ap) to basolateral (Bas), and Bas to Ap) studies. Transport rates were equivalent in both directions for vigabatrin, gabapentin, phenobarbitone, lamotrigine and carbamazepine, being 0.7 x 10- 6, 0.1 x 10- 6, 34 x 10- 6, 36 x 10- 6 and 55 x 10- 6 cm/s, respectively. Phenytoin displayed a 20% increase in Ap to Bas transport, while topiramate and ethosuximide each had greater transport in the uptake direction, with both drugs showing no efflux. None of the transport rates for these drugs were affected by P-gp inhibitors. However, the efflux rate for acetazolamide was 3-fold higher than its uptake and this was significantly reduced by P-gp inhibitors. Thus, only one anti-epileptic, acetazolamide, was shown to be weak P-gp substrate, suggesting that P-gp efflux may not be a factor in relation to the development of resistance of epilepsy therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16882549     DOI: 10.1080/10611860600720814

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  13 in total

1.  Role of P glycoprotein in absorption of novel antimalarial drugs.

Authors:  Andrew Crowe; Kenneth F Ilett; Harin A Karunajeewa; Kevin T Batty; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2006-08-17       Impact factor: 5.191

2.  Antiepileptic drug transport--of mice and men.

Authors:  Graeme J Sills
Journal:  Epilepsy Curr       Date:  2008 Mar-Apr       Impact factor: 7.500

3.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

Review 4.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

5.  Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats.

Authors:  René Holm; Morten A Kall; Sidsel Frølund; Andreas L Nielsen; Anne Jensen; Mie Larsen Broberg; Carsten Uhd Nielsen
Journal:  Pharm Res       Date:  2012-01-11       Impact factor: 4.200

6.  CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity.

Authors:  Sean Hennessy; Charles E Leonard; Cristin P Freeman; Joshua P Metlay; Xin Chu; Brian L Strom; Warren B Bilker
Journal:  J Clin Pharmacol       Date:  2009-07-17       Impact factor: 3.126

7.  The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins.

Authors:  Carlos Luna-Tortós; Bernhard Rambeck; Uwe H Jürgens; Wolfgang Löscher
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

8.  A multi-system approach assessing the interaction of anticonvulsants with P-gp.

Authors:  David Dickens; Siti R Yusof; N Joan Abbott; Babette Weksler; Ignacio A Romero; Pierre-Olivier Couraud; Ana Alfirevic; Munir Pirmohamed; Andrew Owen
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 9.  Pharmacogenetics of chronic pain and its treatment.

Authors:  Svatopluk Světlík; Karolína Hronová; Hana Bakhouche; Olga Matoušková; Ondřej Slanař
Journal:  Mediators Inflamm       Date:  2013-05-20       Impact factor: 4.711

10.  Fexofenadine hydrochloride in the treatment of allergic disease: a review.

Authors:  David Axelrod; Leonard Bielory
Journal:  J Asthma Allergy       Date:  2008-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.